Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual MeetingPRNewsWire • 03/24/22
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/11/22
Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/11/22
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022PRNewsWire • 02/11/22
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/04/22
Neurocrine Biosciences: Taking Advantage Of A Shrinking Share Price Ahead Of Projected GrowthSeeking Alpha • 01/30/22
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial ResultsPRNewsWire • 01/25/22
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program MilestonesPRNewsWire • 01/06/22
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/03/22
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle MovementBenzinga • 12/08/21
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington DiseasePRNewsWire • 12/07/21
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric DisordersPRNewsWire • 11/22/21
Neurocrine Biosciences: Generic Drug Stock Seen As Underpriced By Market-Makers For Near GainsSeeking Alpha • 11/08/21
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/02/21